Lead Product(s) : Liafensine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Fast Track For DB104 in Treatment-Resistant Depression
Details : DB104 (liafensine) is a first–in–class triple reuptake inhibitor. It is being evaluated for the treatment of patients with treatment-resistant depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : Liafensine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liafensine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Denovo Biopharma Announces Breakthrough in Treatment-Resistant Depression
Details : DB104 (liafensine) is a first-in-class triple reuptake inhibitor targeting serotonin, norepinephrine, and dopamine transporters, being studied for treatment-resistant depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : Liafensine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liafensine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Curia
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Denovo discovered a novel genetic biomarker for DB104 (liafensine) efficacy using its unique machine learning approach with whole genome sequencing to identify biomarkers that may be predictive of a patient's response to a specific medicine.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2022
Lead Product(s) : Liafensine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Curia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Liafensine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Liafensine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Treatment-Resistant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2021
Lead Product(s) : Liafensine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable